Details

Autor(en) / Beteiligte

• Chirshev, Evgeny
• Oberg, Kerby C.
• Ioffe, Yevgeniya J.
• Unternaehrer, Juli J.

Titel

Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer

Ist Teil von

• Clinical and translational medicine, 2019-08, Vol.8 (1), p.1-14

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2019

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Abnormal regulation and expression of microRNAs (miRNAs) has been documented in various diseases including cancer. The miRNA let - 7 (MIRLET7) family controls developmental timing and differentiation. Let - 7 loss contributes to carcinogenesis via an increase in its target oncogenes and stemness factors. Let - 7 targets include genes regulating the cell cycle, cell signaling, and maintenance of differentiation. It is categorized as a tumor suppressor because it reduces cancer aggressiveness, chemoresistance, and radioresistance. However, in rare situations let - 7 acts as an oncogene, increasing cancer migration, invasion, chemoresistance, and expression of genes associated with progression and metastasis. Here, we review let - 7 function as tumor suppressor and oncogene, considering let - 7 as a potential diagnostic and prognostic marker, and a therapeutic target for cancer treatment. We explain the complex regulation and function of different let - 7 family members, pointing to abnormal processes involved in carcinogenesis. Let - 7 is a promising option to complement conventional cancer therapy, but requires a tumor specific delivery method to avoid toxicity. While let - 7 therapy is not yet established, we make the case that assessing its tumor presence is crucial when choosing therapy. Clinical data demonstrate that let - 7 can be used as a biomarker for rational precision medicine decisions, resulting in improved patient survival.